-
Je něco špatně v tomto záznamu ?
Real-world Outcomes and Predictive Biomarkers for 177Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate Cancer: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Observational Study
M. Kafka, A. Horninger, G. di Santo, I. Virgolini, H. Neuwirt, LM. Unterrainer, SC. Kunte, E. Deiss, P. Paffenholz, A. Heidenreich, S. Rasul, H. Einspieler, SF. Shariat, P. Rajwa, R. Dozauer, I. Tsaur, E. Medlock, N. Rölz, S. Rausch, C. la...
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, pozorovací studie, multicentrická studie
- MeSH
- antigeny povrchové metabolismus MeSH
- glutamátkarboxypeptidasa II metabolismus MeSH
- lidé středního věku MeSH
- lidé MeSH
- ligandy MeSH
- lutecium * terapeutické užití MeSH
- metastázy nádorů MeSH
- nádorové biomarkery krev MeSH
- nádory prostaty rezistentní na kastraci * patologie radioterapie farmakoterapie MeSH
- prostatický specifický antigen krev MeSH
- radionuklidy terapeutické užití MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- pozorovací studie MeSH
- Geografické názvy
- Evropa MeSH
BACKGROUND: The European Association of Urology guidelines include the lutetium-177 (177Lu) PSMA-617 prostate-specific membrane antigen (PSMA) ligand as a therapy option for metastatic castration-resistant prostate cancer (mCRPC). A major challenge in clinical practice is to pursue a personalized treatment approach based on robust predictive biomarkers. OBJECTIVE: To assess the performance of 177Lu PSMA in real-world practice and to elaborate clinical biomarkers for evaluating treatment responses. DESIGN, SETTING, AND PARTICIPANTS: We conducted a retrospective observational study including 233 patients with mCRPC treated with 177Lu PSMA in eight high-volume European centers. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Baseline characteristics and clinical parameters during and after 177Lu PSMA treatment were documented. Correlations to treatment response were analyzed using χ2 and log-rank tests, with differences between groups with and without disease progression calculated using a Mann-Whitney U test. Univariate and multivariate-adjusted hazard ratios (HRs) were measured using Cox proportional hazards models. RESULTS AND LIMITATIONS: A prostate-specific antigen (PSA) decrease of ≥30% was observed in 41.7%, 63.5%, and 77.8% of patients after the first, second, and third treatment cycle, respectively. Restaging performed via PSMA positron emission tomography-computed tomography revealed that 33.7% of patients had an imaging-based response, including two patients with a complete response, while 13.4% had stable disease. The median time to progression was 5 mo and the median time until the start of a consecutive antineoplastic therapy was 8.5 mo. Of importance, a PSA decrease ≥30% after the first two cycles of 177Lu PSMA (1 cycle: p = 0.0003; 2 cycles: p = 0.004), absolute PSA after the first three cycles (1 cycle: p = 0.011; 2 cycles: p = 0.0005; 3 cycles: p = 0.002), and a PSA doubling time >6 mo (p = 0.009) were significantly correlated to treatment response. Furthermore, gamma-glutamyl transferase ≤31 U/L at the start of 177Lu PSMA therapy was correlated with 1.5 times higher risk of progression for patients without but not with visceral metastases (p = 0.046). CONCLUSIONS: 177Lu PSMA is an effective treatment option in mCRPC in the real-world setting. A PSA decrease ≥30% after the first two cycles is an early marker of response that can be easily implemented in clinical practice. PATIENT SUMMARY: 177Lu PSMA is a radioactive agent approved for treatment of advanced prostate cancer. We reviewed its use outside of clinical trials for patients treated at eight European centers. We found that 177Lu PSMA is an effective treatment option in real-world practice. A PSA (prostate-specific antigen) decrease of ≥30% after the first two therapy cycles is an early indicator of response to treatment and can be used in personalizing treatments for patients.
Department of Nuclear Medicine Medical University Innsbruck Innsbruck Austria
Department of Nuclear Medicine University Hospital LMU Munich Munich Germany
Department of Nuclear Medicine University Hospital Tübingen Tübingen Germany
Department of Urology 2nd Faculty of Medicine Charles University Prague Czechia
Department of Urology and Pediatric Urology University Medical Center Mainz Mainz Germany
Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria
Department of Urology Medical University Innsbruck Innsbruck Austria
Department of Urology Medical University of Silesia Zabrze Poland
Department of Urology Medical University of Vienna Vienna Austria
Department of Urology University Hospital Schleswig Holstein Campus Lübeck Lübeck Germany
Department of Urology University Hospital Tübingen Tübingen Germany
Department of Urology University of Texas Southwestern Dallas TX USA
Department of Urology Weill Cornell Medicine New York NY USA
Department Surgery Oncology and Gastroenterology Urologic Unit University of Padova Padova Italy
Division of Nuclear Medicine Medical University of Vienna Vienna Austria
Karl Landsteiner Institute of Urology and Andrology Vienna Austria
Radiation Oncology Unit Veneto Institute of Oncology IRCCS Padua Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24013822
- 003
- CZ-PrNML
- 005
- 20240905134354.0
- 007
- ta
- 008
- 240725s2024 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.euo.2023.07.018 $2 doi
- 035 __
- $a (PubMed)37604763
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Kafka, Mona $u Department of Urology, Medical University Innsbruck, Innsbruck, Austria
- 245 10
- $a Real-world Outcomes and Predictive Biomarkers for 177Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate Cancer: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Observational Study / $c M. Kafka, A. Horninger, G. di Santo, I. Virgolini, H. Neuwirt, LM. Unterrainer, SC. Kunte, E. Deiss, P. Paffenholz, A. Heidenreich, S. Rasul, H. Einspieler, SF. Shariat, P. Rajwa, R. Dozauer, I. Tsaur, E. Medlock, N. Rölz, S. Rausch, C. la Fougère, N. Trautwein, MC. Roesch, AS. Merseburger, F. Zattoni, M. Sepulcri, M. Ladurner, J. Bektic, G. Gandaglia, W. Horninger, I. Heidegger
- 520 9_
- $a BACKGROUND: The European Association of Urology guidelines include the lutetium-177 (177Lu) PSMA-617 prostate-specific membrane antigen (PSMA) ligand as a therapy option for metastatic castration-resistant prostate cancer (mCRPC). A major challenge in clinical practice is to pursue a personalized treatment approach based on robust predictive biomarkers. OBJECTIVE: To assess the performance of 177Lu PSMA in real-world practice and to elaborate clinical biomarkers for evaluating treatment responses. DESIGN, SETTING, AND PARTICIPANTS: We conducted a retrospective observational study including 233 patients with mCRPC treated with 177Lu PSMA in eight high-volume European centers. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Baseline characteristics and clinical parameters during and after 177Lu PSMA treatment were documented. Correlations to treatment response were analyzed using χ2 and log-rank tests, with differences between groups with and without disease progression calculated using a Mann-Whitney U test. Univariate and multivariate-adjusted hazard ratios (HRs) were measured using Cox proportional hazards models. RESULTS AND LIMITATIONS: A prostate-specific antigen (PSA) decrease of ≥30% was observed in 41.7%, 63.5%, and 77.8% of patients after the first, second, and third treatment cycle, respectively. Restaging performed via PSMA positron emission tomography-computed tomography revealed that 33.7% of patients had an imaging-based response, including two patients with a complete response, while 13.4% had stable disease. The median time to progression was 5 mo and the median time until the start of a consecutive antineoplastic therapy was 8.5 mo. Of importance, a PSA decrease ≥30% after the first two cycles of 177Lu PSMA (1 cycle: p = 0.0003; 2 cycles: p = 0.004), absolute PSA after the first three cycles (1 cycle: p = 0.011; 2 cycles: p = 0.0005; 3 cycles: p = 0.002), and a PSA doubling time >6 mo (p = 0.009) were significantly correlated to treatment response. Furthermore, gamma-glutamyl transferase ≤31 U/L at the start of 177Lu PSMA therapy was correlated with 1.5 times higher risk of progression for patients without but not with visceral metastases (p = 0.046). CONCLUSIONS: 177Lu PSMA is an effective treatment option in mCRPC in the real-world setting. A PSA decrease ≥30% after the first two cycles is an early marker of response that can be easily implemented in clinical practice. PATIENT SUMMARY: 177Lu PSMA is a radioactive agent approved for treatment of advanced prostate cancer. We reviewed its use outside of clinical trials for patients treated at eight European centers. We found that 177Lu PSMA is an effective treatment option in real-world practice. A PSA (prostate-specific antigen) decrease of ≥30% after the first two therapy cycles is an early indicator of response to treatment and can be used in personalizing treatments for patients.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a nádory prostaty rezistentní na kastraci $x patologie $x radioterapie $x farmakoterapie $7 D064129
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a lutecium $x terapeutické užití $7 D008187
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a nádorové biomarkery $x krev $7 D014408
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a radionuklidy $x terapeutické užití $7 D011868
- 650 _2
- $a glutamátkarboxypeptidasa II $x metabolismus $7 D043425
- 650 _2
- $a antigeny povrchové $x metabolismus $7 D000954
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a prostatický specifický antigen $x krev $7 D017430
- 650 _2
- $a ligandy $7 D008024
- 650 _2
- $a metastázy nádorů $7 D009362
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a pozorovací studie $7 D064888
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Horninger, Andreas $u Department of Urology, Medical University Innsbruck, Innsbruck, Austria
- 700 1_
- $a di Santo, Gianpaolo $u Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria
- 700 1_
- $a Virgolini, Irene $u Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria
- 700 1_
- $a Neuwirt, Hannes $u Department of Internal Medicine IV - Nephrology and Hypertension, Medical University Innsbruck, Innsbruck, Austria
- 700 1_
- $a Unterrainer, Lena M $u Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany
- 700 1_
- $a Kunte, Sophie C $u Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany
- 700 1_
- $a Deiss, Emil $u Department of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic Surgery, University of Cologne and University Hospital Cologne, Cologne, Germany
- 700 1_
- $a Paffenholz, Pia $u Department of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic Surgery, University of Cologne and University Hospital Cologne, Cologne, Germany
- 700 1_
- $a Heidenreich, Axel $u Department of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic Surgery, University of Cologne and University Hospital Cologne, Cologne, Germany
- 700 1_
- $a Rasul, Sazan $u Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Einspieler, Holger $u Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University of Texas Southwestern, Dallas, TX, USA; Department of Urology, Weill Cornell Medicine, New York, NY, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czechia; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Medical University of Silesia, Zabrze, Poland
- 700 1_
- $a Rajwa, Pawel $u Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Medical University of Silesia, Zabrze, Poland
- 700 1_
- $a Dozauer, Robert $u Department of Urology and Pediatric Urology, University Medical Center Mainz, Mainz, Germany
- 700 1_
- $a Tsaur, Igor $u Department of Urology and Pediatric Urology, University Medical Center Mainz, Mainz, Germany
- 700 1_
- $a Medlock, Ellen $u Department of Urology and Pediatric Urology, University Medical Center Mainz, Mainz, Germany
- 700 1_
- $a Rölz, Niklas $u Department of Urology and Pediatric Urology, University Medical Center Mainz, Mainz, Germany
- 700 1_
- $a Rausch, Steffen $u Department of Urology, University Hospital Tübingen, Tübingen, Germany
- 700 1_
- $a la Fougère, Christian $u Department of Nuclear Medicine University Hospital Tübingen, Tübingen, Germany
- 700 1_
- $a Trautwein, Nils $u Department of Nuclear Medicine University Hospital Tübingen, Tübingen, Germany
- 700 1_
- $a Roesch, Marie C $u Department of Urology, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany
- 700 1_
- $a Merseburger, Axel S $u Department of Urology, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany
- 700 1_
- $a Zattoni, Fabio $u Department Surgery, Oncology and Gastroenterology, Urologic Unit, University of Padova, Padova, Italy
- 700 1_
- $a Sepulcri, Matteo $u Radiation Oncology Unit, Veneto Institute of Oncology IRCCS, Padua, Italy
- 700 1_
- $a Ladurner, Michael $u Department of Urology, Medical University Innsbruck, Innsbruck, Austria
- 700 1_
- $a Bektic, Jasmin $u Department of Urology, Medical University Innsbruck, Innsbruck, Austria
- 700 1_
- $a Gandaglia, Giorgio $u Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Laboratory, IRCCS San Raffaele Scientific Institute, Milan, Italy
- 700 1_
- $a Horninger, Wolfgang $u Department of Urology, Medical University Innsbruck, Innsbruck, Austria
- 700 1_
- $a Heidegger, Isabel $u Department of Urology, Medical University Innsbruck, Innsbruck, Austria. Electronic address: isabel-maria.heidegger@i-med.ac.at
- 773 0_
- $w MED00205913 $t European urology oncology $x 2588-9311 $g Roč. 7, č. 3 (2024), s. 421-429
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37604763 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905134348 $b ABA008
- 999 __
- $a ok $b bmc $g 2143563 $s 1225688
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 7 $c 3 $d 421-429 $e 20230819 $i 2588-9311 $m European urology oncology $n Eur Urol Oncol $x MED00205913
- LZP __
- $a Pubmed-20240725
